• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

Traditional therapies and medications do not work for many people suffering from depression. Personalized treatment may be the answer.

Cue is an intervention platform for digital devices that translates passively acquired normal sensor data from smartphones into customized micro-interventions to improve mental health. We analysed the best-fit personalized ML models for each subject using Shapley values to identify their feature predictors and uncover distinct characteristics that can be used to predict changes in mood with time.

Predictors of Mood

Depression is one of the leading causes of mental illness.1 Yet, only half of those who have the condition receive treatment1. In order to improve outcomes, clinicians need to be able to recognize and treat patients who have the highest chance of responding to specific treatments.

A customized depression treatment is one method to achieve this. Researchers at the University of Illinois Chicago are developing new methods for predicting which patients will benefit the most from specific treatments. They are using sensors on mobile phones and a voice assistant incorporating artificial intelligence as well as other digital tools. Two grants worth more than $10 million will be used to determine biological and behavioral indicators of response.

The majority of research on predictors for depression treatment effectiveness has been focused on clinical and sociodemographic characteristics. These include demographic variables like age, sex and educational level, clinical characteristics like symptoms severity and comorbidities and biological markers like neuroimaging and genetic variation.

Few studies have used longitudinal data to predict mood of individuals. Few studies also take into account the fact that mood can differ significantly between individuals. Therefore, it is critical to develop methods that permit the recognition of different mood predictors for each person and treatment effects.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This allows the team to develop algorithms that can identify different patterns of behavior and emotions that vary between individuals.

In addition to these methods, the team created a machine learning algorithm to model the changing variables that influence each person's mood. The algorithm combines these personal variations into a distinct "digital phenotype" for each participant.

This digital phenotype was correlated with CAT-DI scores, which is a psychometrically validated symptom severity scale. The correlation was weak however (Pearson r = 0,08, P-value adjusted for BH = 3.55 x 10 03) and varied significantly between individuals.

Predictors of symptoms

Depression is one of the most prevalent causes of disability1 yet it is often not properly diagnosed and treated. Depressive disorders are often not treated because of the stigma that surrounds them, as well as the lack of effective treatments.

To aid in the development of a personalized treatment plan to improve treatment, identifying the patterns that can predict symptoms is essential. Current prediction methods rely heavily on clinical interviews, which aren't reliable and only identify a handful of characteristics that are associated with depression.

Machine learning is used to blend continuous digital behavioral phenotypes that are captured by sensors on smartphones and a validated online mental health tracker (the Computerized Adaptive Testing Depression Inventory, the CAT-DI) with other predictors of severity of symptoms has the potential to improve the accuracy of diagnosis and treatment efficacy for depression. Digital phenotypes permit continuous, high-resolution measurements and capture a variety of unique behaviors and activity patterns that are difficult to record through interviews.

The study included University of California Los Angeles (UCLA) students with moderate to severe depressive symptoms. participating in the Screening and Treatment for Anxiety and Depression (STAND) program29 that was created under the UCLA Depression Grand Challenge. Participants were routed to online support or in-person clinical care depending on their depression treatment uk severity. Participants with a CAT-DI score of 35 65 students were assigned online support by an instructor and those with scores of 75 patients were referred for psychotherapy in-person.

At the beginning, participants answered a series of questions about their personal characteristics and psychosocial traits. The questions covered education, age, sex and gender and marital status, financial status, whether they were divorced or not, the frequency of suicidal thoughts, intent or attempts, and the frequency with which they consumed alcohol. Participants also rated their degree of morning depression treatment severity on a 0-100 scale using the CAT-DI. CAT-DI assessments were conducted each week for those who received online support and once a week for those receiving in-person treatment.

Predictors of treatment for panic attacks and depression Response

Research is focusing on personalization of treatment for depression. Many studies are aimed at identifying predictors, which will help doctors determine the most effective drugs for each person. Particularly, pharmacogenetics can identify genetic variants that influence how to treat anxiety and depression without medication the body metabolizes antidepressants. This allows doctors to select the medications that are most likely to be most effective for each patient, while minimizing the time and effort in trials and errors, while eliminating any side effects that could otherwise hinder advancement.

Another option is to develop prediction models that combine clinical data and neural imaging data. These models can be used to determine the most appropriate combination of variables that are predictors of a specific outcome, such as whether or not a medication will improve the mood and symptoms. These models can be used to predict the response of a patient to a treatment, allowing doctors to maximize the effectiveness of their treatment.

A new generation uses machine learning methods such as algorithms for classification and supervised learning, regularized logistic regression and tree-based techniques to combine the effects of several variables to improve the accuracy of predictive. These models have proven to be effective in the prediction of treatment outcomes like the response to antidepressants. These approaches are becoming more popular in psychiatry and could become the norm in the future clinical practice.

Research into depression's underlying mechanisms continues, as do ML-based predictive models. Recent research suggests that depression is linked to dysfunctions in specific neural networks. This suggests that an individualized treatment for depression will be based upon targeted therapies that restore normal function to these circuits.

One method of doing this is by using internet-based programs that can provide a more individualized and tailored experience for patients. For example, one study found that a web-based program was more effective than standard care in alleviating symptoms and ensuring the best quality of life for those with MDD. A controlled study that was randomized to an individualized treatment for depression revealed that a significant percentage of patients experienced sustained improvement as well as fewer side negative effects.

Predictors of side effects

In the treatment of depression, the biggest challenge is predicting and determining which antidepressant medications will have no or minimal negative side negative effects. Many patients have a trial-and error method, involving a variety of medications prescribed until they find one that is safe and effective. Pharmacogenetics offers a new and exciting method to choose antidepressant medications that is more efficient and targeted.

There are a variety of predictors that can be used to determine the antidepressant to be prescribed, such as gene variations, phenotypes of the patient such as ethnicity or gender and co-morbidities. However it is difficult to determine the most reliable and accurate factors that can predict the effectiveness of a particular treatment will probably require randomized controlled trials of much larger samples than those normally enrolled in clinical trials. This is because it could be more difficult to detect the effects of moderators or interactions in trials that only include a single episode per person instead of multiple episodes over a period of time.

Additionally, the prediction of a patient's reaction to a particular medication will likely also require information on comorbidities and symptom profiles, and the patient's previous experience with tolerability and efficacy. Currently, only some easily assessable sociodemographic and clinical variables are believed to be correlated with response to MDD factors, including gender, age race/ethnicity, SES BMI, the presence of alexithymia, and the severity of depressive symptoms.

There are many challenges to overcome in the application of pharmacogenetics for depression treatment. It is crucial to have a clear understanding and definition of the genetic factors that cause depression, and an understanding of an accurate predictor of treatment response. In addition, ethical issues, such as privacy and the ethical use of personal genetic information, must be carefully considered. Pharmacogenetics could be able to, over the long term, reduce stigma surrounding mental health treatments and improve the outcomes of treatment. Like any other psychiatric treatment it is crucial to give careful consideration and implement the plan. At present, it's recommended to provide patients with a variety of medications for depression that are effective and urge them to speak openly with their doctor.